H6Z Stock Overview
A biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$1.03 |
| 52 Week Low | US$0.33 |
| Beta | 0.55 |
| 11 Month Change | 75.00% |
| 3 Month Change | 9.57% |
| 1 Year Change | -11.89% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| H6Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.1% | 2.6% | 4.5% |
| 1Y | -11.9% | -16.4% | 13.4% |
Return vs Industry: H6Z exceeded the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: H6Z underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| H6Z volatility | |
|---|---|
| H6Z Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H6Z's share price has been volatile over the past 3 months.
Volatility Over Time: H6Z's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 758 | Wang Xu | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
| H6Z fundamental statistics | |
|---|---|
| Market cap | €143.08m |
| Earnings (TTM) | -€55.37m |
| Revenue (TTM) | €73.25m |
2.0x
P/S Ratio-2.6x
P/E RatioIs H6Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H6Z income statement (TTM) | |
|---|---|
| Revenue | CN¥573.42m |
| Cost of Revenue | CN¥187.36m |
| Gross Profit | CN¥386.06m |
| Other Expenses | CN¥819.52m |
| Earnings | -CN¥433.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 67.33% |
| Net Profit Margin | -75.59% |
| Debt/Equity Ratio | 71.3% |
How did H6Z perform over the long term?
See historical performance and comparison